<qa>  What is the HSPPC-96 vaccine administered?- Phase I closed to accrual as of 7252007: Patients undergo surgical resection. Viable tumor tissue is used to generate the gp96 heat shock protein-peptide complex HSPPC-96 vaccine. Patients with primary disease receive standard adjuvant therapy after surgery. Patients whose disease progresses during or after standard adjuvant therapy receive the HSPPC-96 vaccine. Patients with recurrent disease receive the HSPPC-96 vaccine between 2-8 weeks after surgery. The HSPPC-96 vaccine is administered intradermally every 1-3 weeks for 4 doses and then every 2-3 weeks thereafter in the absence of disease progression, unacceptable toxicity, or vaccine depletion. 